中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.029 seconds)

    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    1.
    发明申请
    PRMT1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
    PRMT1对靶基因的治疗和诊断

    公开(公告)号：WO2010023877A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/004091

    申请日：2009-08-25

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  HAMAMOTO, Ryuji ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  HAMAMOTO, Ryuji ,  TOGASHI, Akira

    IPC: C12Q1/68 ,  C12N15/00

    CPC classification number: C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01125 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2500/10

    Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.

    Abstract translation: 本文描述了用于诊断发展中的癌症，特别是膀胱癌，胃癌，结肠直肠癌，乳腺癌，食管癌，肺癌，淋巴瘤，胰腺癌和睾丸癌的易感性的客观方法。 在一个实施方案中，诊断方法包括确定PRMT1基因的表达水平。 本发明还提供筛选用于治疗PRMT1相关疾病例如癌症的治疗剂的方法，例如癌症。 膀胱癌，胃癌，结肠直肠癌，乳腺癌，食管癌，肺癌，淋巴瘤，胰腺癌和睾丸癌。 本发明还提供了抑制细胞生长和治疗或减轻PRMT1相关疾病症状的方法。 本发明还涉及包括双链分子和编码它们的载体以及包含它们的组合物的产品。

    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    2.
    发明申请
    C12ORF48 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
    C12ORF48作为癌症治疗和诊断的靶基因

    公开(公告)号：WO2010023855A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/004020

    申请日：2009-08-21

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  NAKAGAWA, Hidewaki ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  NAKAGAWA, Hidewaki ,  TOGASHI, Akira

    IPC: C12N15/09

    CPC classification number: C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2500/10

    Abstract: Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.

    Abstract translation: 本文描述了用于诊断发展胰腺癌和前列腺癌，特别是胰腺导管腺癌（PDAC）和去势抗性前列腺癌的倾向的客观方法。 在一个实施方案中，诊断方法包括使用靶向C12ORF48基因的siRNA确定C12ORF48的表达水平的步骤。 本发明还包括诸如siRNA的产物以及含有它们的组合物。 本发明还提供筛选用于治疗C12ORF48相关疾病（例如癌症）的治疗剂的方法。 胰腺癌和前列腺癌，以及抑制细胞生长和治疗或减轻一种或多种疾病症状的方法。 本发明还包括诸如双链分子的产物，以及含有它们的载体和组合物。

    METHOD FOR TREATING OR PREVENTING BLADDER CANCER USING THE DEPDC1 POLYPEPTIDE
    3.
    发明申请
    METHOD FOR TREATING OR PREVENTING BLADDER CANCER USING THE DEPDC1 POLYPEPTIDE 审中-公开
    使用DEPDC1多肽治疗或预防刮板癌的方法

    公开(公告)号：WO2010023850A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/004006

    申请日：2009-08-21

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  KATAGIRI, Toyomasa ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  KATAGIRI, Toyomasa ,  TOGASHI, Akira

    IPC: C12N15/09 ,  A61K38/00 ,  A61P35/00 ,  C07K14/82 ,  C07K19/00

    CPC classification number: C07K14/82 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/10 ,  C12N15/113 ,  C12N2310/14 ,  G01N33/5011

    Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides composed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZNF224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.

    Abstract translation: 本发明提供使用由包含DEPDC1的多肽片段的氨基酸序列组成的多肽来治疗癌症的治疗剂和方法。 本发明的多肽可以通过用转染试剂例如聚精氨酸修饰多肽而被引入到癌细胞中。 此外，本发明提供筛选用于抑制DEPDC1 / ZNF224复合物形成或治疗癌症的治疗剂或化合物的方法。 本发明还提供靶向ZNF224基因的siRNA，其被认为可用于治疗膀胱癌。

    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    4.
    发明申请
    SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
    SYNGR4用于靶向治疗癌症和诊断基因

    公开(公告)号：WO2010023866A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/004059

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    IPC: C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53

    CPC classification number: C12N15/113 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2500/10

    Abstract: The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.

    Abstract translation: 本发明涉及SYNGR4基因在肺癌致癌作用中的作用，其特征在于通过对一种或多种SYNGR4基因或包含其的组合物，载体或细胞施用双链分子来治疗或预防肺癌的方法 双链分子和抗体。 本发明还具有使用一种或多种选自SYNGR4的过表达基因的肺癌诊断方法或评估/确定患有肺癌，特别是NSCLC或SCLC的患者的预后。 为此，SYNGR4可作为肺癌的新型血清学标志物。 还公开了鉴定用于治疗和预防肺癌的化合物的方法，以其作为肺癌中一种或多种SYNGR4的过度表达的指标作为指标。

    ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER
    7.
    发明申请
    ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER 审中-公开
    ECT2 ONCOGENE作为肺癌和食管癌的治疗目标和预防指标

    公开(公告)号：WO2010007791A1

    公开(公告)日：2010-01-21

    申请号：PCT/JP2009/003360

    申请日：2009-07-16

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    IPC: C12N15/09

    CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2800/50

    Abstract: The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.

    Abstract translation: 本发明特征在于检测肺癌或食管癌的方法，通过检测ECT2与正常器官的过表达。 还公开了基于ECT2在肺癌或食管癌中的过表达，ECT2的细胞增殖功能，鉴定用于治疗和预防肺癌或食管癌的化合物的方法。 此外，提供了通过对ECT2基因施用双链分子或针对ECT2蛋白的抗体来治疗肺癌或食管癌的方法。 本发明还提供了包括双链分子和编码它们的载体的产物，以及可用于所提供的方法中的包含分子或载体的组合物。

    COMPOSITIONS AND METHODS OF TREATING CANCER
    8.
    发明申请
    COMPOSITIONS AND METHODS OF TREATING CANCER 审中-公开
    治疗癌症的组合物和方法

    公开(公告)号：WO2009001562A1

    公开(公告)日：2008-12-31

    申请号：PCT/JP2008/001665

    申请日：2008-06-26

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  TOGASHI, Akira ,  TOBITA, Ryutaro ,  ISHIZAKI, Yuka ,  KONUMA, Akiko

    Inventor： TOGASHI, Akira ,  TOBITA, Ryutaro ,  ISHIZAKI, Yuka ,  KONUMA, Akiko

    IPC: C12N15/00 ,  A61K31/7105 ,  A61K48/00 ,  A61P35/00

    CPC classification number: C12N15/113 ,  C12N2310/14

    Abstract: The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.

    Abstract translation: 本发明的特征在于通过对选自C14orf78，MYBL2，UBE2S和UBE2T的CX基因施用双链核酸分子来治疗癌症的方法。 本发明还包括产物，包括双链核酸分子和编码它们的载体，以及包含所提供方法中有用的分子或载体的组合物。 本发明的方法适用于治疗包括肺癌，乳腺癌，膀胱癌，食道癌，前列腺癌，胆管细胞癌和睾丸精原细胞癌等癌症。

    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    9.
    发明申请
    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
    OIP5作为癌症治疗和诊断的目标基因

    公开(公告)号：WO2010023864A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/004056

    申请日：2009-08-24

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    IPC: C12N15/09 ,  C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

    Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody.The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.

    Abstract translation: 本发明涉及OIP5基因在肺和/或食道癌癌发生中的作用，其特征在于通过对OIP5基因或组合物施用双链分子来治疗和/或预防肺癌和/或食管癌的方法， 含有这种双链分子和抗体的载体或细胞。本发明还涉及用于检测和/或诊断肺癌和/或食管癌的方法，或评估/确定癌症治疗的预后和/或监测癌症治疗的功效的方法 通过检测OIP5的肺和/或食道癌患者。 此外，公开了鉴定用于治疗和预防与OIP5有关的癌症的化合物的方法。

    TBC1D7 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER
    10.
    发明申请
    TBC1D7 AS TUMOR MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
    TBC1D7作为肿瘤标志物和癌症治疗目标

    公开(公告)号：WO2010023838A1

    公开(公告)日：2010-03-04

    申请号：PCT/JP2009/003895

    申请日：2009-08-14

    Applicant: ONCOTHERAPY SCIENCE, INC. ,  NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    Inventor： NAKAMURA, Yusuke ,  DAIGO, Yataro ,  TOGASHI, Akira

    IPC: C12Q1/68 ,  A61K48/00 ,  A61P35/00 ,  C07K7/04 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

    CPC classification number: C07K14/4748 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N33/57423 ,  G01N2333/4703 ,  G01N2500/04

    Abstract: The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the TBC1D7 genes or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing lung or assessing/determining the prognosis of a patient with lung, especially NSCLC or SCLC, or esophageal cancer, using one or more over-expressed genes selected from among TBC1D7. To that end, TBC1D7 may serve as a novel biomarker for lung cancer or esophageal cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung or esophageal cancer, using as an index for their effect on the over-expression of one or more of TBC1D7 in the lung cancer or esophageal cancer.

    Abstract translation: 本发明涉及TBC1D7基因在癌症，特别是肺癌或食管癌中的作用或致癌作用，其特征在于通过施用双重的方法治疗和/或预防癌症，特别是肺癌或食管癌 针对一种或多种TBC1D7基因或包含这种双链分子的组合物，载体或细胞。 本发明还涉及使用一种或多种选自TBC1D7的过表达基因的方法来诊断肺部或评估/确定患有肺，特别是NSCLC或SCLC或食管癌的患者的预后。 为此，TBC1D7可作为肺癌或食管癌的新型生物标志物。 此外，公开了鉴定用于治疗和预防肺或食管癌的化合物的方法，其用作对肺癌或食管癌中TBC1D7中一种或多种的过度表达的影响的指标。

Patent Agency Ranking